Sandoz: 9m sales up 9% at E7.6bn
(CercleFinance.com) - Net sales amounted to $2.
6bn in Q3, up 12% at constant exchange rates y-o-y.
Biosimilars were the main growth driver in the quarter, while generics benefited from solid demand. Growth accelerated in both sectors, it says.
9m 2024 net sales totaled $7.6bn, up 9% at constant exchange rates y-o-y.
Growth was primarily driven by biosimilars, with strong demand for both the core business and new organic and acquired products on the market in the US, Sandoz says.
Thanks to the strong momentum of its biosimilars business and solid demand for generics, the company has raised its net sales guidance for 2024 to high single-digit growth at constant exchange rates compared with the previous year (from mid-to-high single digits), and has confirmed its guidance of a core EBITDA margin of around 20%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
6bn in Q3, up 12% at constant exchange rates y-o-y.
Biosimilars were the main growth driver in the quarter, while generics benefited from solid demand. Growth accelerated in both sectors, it says.
9m 2024 net sales totaled $7.6bn, up 9% at constant exchange rates y-o-y.
Growth was primarily driven by biosimilars, with strong demand for both the core business and new organic and acquired products on the market in the US, Sandoz says.
Thanks to the strong momentum of its biosimilars business and solid demand for generics, the company has raised its net sales guidance for 2024 to high single-digit growth at constant exchange rates compared with the previous year (from mid-to-high single digits), and has confirmed its guidance of a core EBITDA margin of around 20%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.